About 50% of the 13.9 million people undergoing treatment in the US for major depressive disorder have anxious depression, which represents a large market opportunity for Neuronetics, according to an analyst.
Neuronetics, Inc. announced on 19 July the US Food and Drug Administration cleared its NeuroStar transcranial magnetic stimulation system (TMS) for anxious depression based on results from a real-world study. The system was previously cleared to treat obsessive-compulsive disorder.
BTIG analyst Marie Thibault wrote in her 19 July report that the extended label is a “positive update that, along...
Healthcare product industries await publication of the NHS 10-Year Plan, due out the coming days, which will focus on health generally not just the NHS, UK health secretary Wes Streeting said during a final prelaunch event on 24 June.
From June 30, new European Commission rules will attempt to redress an imbalance in medtech trade between the EU and the People’s Republic of China.
Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.
